Traders should watch for the ESMO 2026 presentation (Oct 23-27) for updated zolucatetide data in desmoid tumors, which could be a major catalyst. The Q4 2026 FDA interaction for Phase 3 alignment and initiation of the Phase 3 trial in 1H 2027 are key milestones. The strong cash runway into 2030 reduces near-term dilution risk, but the clinical-stage nature means binary outcomes on pipeline data.
Price Chart
Executive Summary
Parabilis Medicines reported Q2 2026 results with a net loss of $52.5M, wider than the $34.8M loss in Q2 2025, driven by increased R&D and G&A spending. The company ended the quarter with $1.1B in cash following a $770.5M IPO and a $125M Regeneron collaboration, funding operations into 2030. Key catalysts include maturing Phase 1/2 data for zolucatetide in desmoid tumors in Q4 2026 and a planned Phase 3 registrational trial initiation in 1H 2027.
Key Financial Metrics
Key Facts
- Net loss of $52.5M in Q2 2026 vs $34.8M in Q2 2025, driven by increased R&D ($39.4M vs $30.1M) and G&A ($11.7M vs $6.4M) expenses.
- Cash, cash equivalents and marketable securities of $1.1B as of June 30, 2026, up from $27.7M at Dec 31, 2025, expected to fund operations into 2030.
- Completed upsized IPO raising $770.5M and a $125M Regeneron collaboration ($50M upfront + $75M equity investment) with potential for up to $2.2B in milestones plus tiered royalties.
- Zolucatetide Phase 1/2 data in desmoid tumors accepted for oral presentation at ESMO 2026 (Oct 23-27); more mature data expected Q4 2026; Phase 3 registrational trial planned for 1H 2027.
- FAP cohort enrollment expected H2 2026; ACP data expected 1H 2027; NEJM publication showed durable response in ameloblastoma.
- Collaboration with Regeneron to develop Antibody-Helicon Conjugates (AHCs) expands platform application.
- Strengthened leadership with appointments of CFO, Chief Business & Strategy Officer, and new Board member.
- Net loss per share allocable to common stockholders was $(2.32) for Q2 2026 vs $(22.28) for Q2 2025, reflecting increased share count post-IPO.
Financial Impact
Net loss widened by $17.7M YoY to $52.5M; cash position strengthened by $1.07B to $1.1B; IPO raised $770.5M; Regeneron deal provided $125M upfront with up to $2.2B in milestones.
Risk Factors
- Clinical-stage biotech with no approved products; pipeline entirely dependent on zolucatetide and Helicon platform success.
- Net loss widening as R&D and G&A expenses increase; operating losses expected to continue.
- Phase 3 trial initiation and regulatory interactions in 2027 carry execution risk.
- Competition from other Wnt/β-catenin targeting therapies and desmoid tumor treatments.
- Dependence on Regeneron collaboration for AHC development; milestone payments contingent on success.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344336 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 24, 2026 2d ago | Press Release | $24.79 | awaiting T+60 | — | $25.03 (+0.97%) |
Oct 19, 2026 7d ago | Press Release | $25.35 | awaiting T+60 | — | $25.03 (−1.26%) |
Sep 15, 2026 5w ago | 8-K | $36.88 | awaiting T+60 | — | $25.03 (−32.13%) |
Sep 2, 2026 7w ago | 8-K | $40.75 | awaiting T+60 | — | $25.03 (−38.58%) |
Aug 13, 2026 10w ago | 8-K | $35.67 | awaiting T+60 | — | $25.03 (−29.83%) |
Aug 13, 2026 10w ago | Press Release | $35.67 | awaiting T+60 | — | $25.03 (−29.83%) |
Jul 22, 2026 13w ago | Insider Buy | $32.81 $22.75 | ▼ −30.66% | ▼ −34.31% | $25.03 (−23.71%) |
Jun 29, 2026 17w ago | Insider Cluster | $29.19 $33.31 | ▲ +14.11% | ▲ +10.50% | $25.03 (−14.25%) |
Jun 16, 2026 18w ago | Insider Cluster | $26.03 $36.16 | ▲ +38.92% | ▲ +36.23% | $25.03 (−3.84%) |
Jun 15, 2026 18w ago | Insider Cluster | $26.59 $36.88 | ▲ +38.70% | ▲ +36.84% | $25.03 (−5.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers